FDA Lifts Curtain On Homeopathics Regulatory Evaluation With Public Hearing
This article was originally published in The Tan Sheet
Executive Summary
FDA’s public hearing announcement comes a week after it alerted consumers to the prevalence of homeopathics with violative indications for treating asthma and could signal the start of the separate review of homeopathic regulations the agency said it would undertake when the OTC drug review began in 1972.
You may also be interested in...
FDA Urged To Change OTC Monograph System, But Not In Midstream
“Moving away from the monograph system when we are so close to the end” would “risk setting back the OTC drug review many years or even decades,” CHPA head Scott Melville says at an FDA public hearing. Other stakeholder s explain how the monograph system has failed industry and consumers.
Flu Therapy “Scammers” Prompt FDA, FTC Warnings
Recent FDA warning letters include one to Oasis Consumer Healthcare regarding marketing and labeling for Halo Oral Antiseptic Spray. The agency also teamed with FTC to warn three online health stores for making flu claims for supplement products.
Science-Based Evaluation Advocates Want Tighter Homeopathic Oversight
Public health concerns should prompt FDA to tighten its regulation of homeopathic drugs, a citizen petition filed by the nonprofit Center for Inquiry says.